Matthew Harrison

In a report published Monday, Morgan Stanley analyst Matthew Harrison reiterated an Equal-Weight rating on Pharmacyclics (NASDAQ: PCYC), but removed the $100.00 price target. In the report, Morgan Stanley noted, “Two key Imbruvica datasets were presented. The analyst event (6/2) and 3yr follow-up...

In a report published Tuesday, Morgan Stanley analyst Matthew Harrison reiterated an Equal-Weight rating on Pharmacyclics (NASDAQ: PCYC), but removed the $100.00 price target. In the report, Morgan Stanley noted, “We performed a detailed IMS launch analysis that suggests 2014 nums are too low, but...

In a report published Monday, Morgan Stanley analyst Matthew Harrison reiterated an Overweight rating on Amgen (NASDAQ: AMGN), but removed the $140.00 price target. In the report, Morgan Stanley noted, “The AMAGINE-1 study is the 1st of three PhIII studies for brodalumab (AMAGINE-2 & 3 are...

In a report published Monday, Morgan Stanley analyst Matthew Harrison reiterated an Equal-Weight rating on Celgene (NASDAQ: CELG), but removed the $150.00 price target. In the report, Morgan Stanley noted, “The Markman hearing's main purpose is for Celgene and Natco (the generic filer) to present...

On Thursday, Morgan Stanley initiated coverage on a number of biotech companies, rating both Amgen (NASDAQ: AMGN) and Biogen (NASDAQ: BIIB) at Overweight. Analyst Matthew Harrison expects total group revenues to “double from $175B over the last 5 years to $335B over the next 5 years and total...